JS212 + JS213

JS212 + JS213 is an investigational combination regimen consisting of JS212, a recombinant humanized bispecific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) conjugated to a topoisomerase I inhibitor payload (exatecan), and JS213, a bifunctional antibody fusion protein targeting programmed cell death protein 1 (PD-1) and interleukin-2 (IL-2). Developed by Junshi Biosciences, this combination is designed to leverage the synergistic effects of dual-receptor targeted cytotoxic delivery and dual-pathway immune checkpoint inhibition/activation. JS212 delivers a potent cytotoxic payload directly to tumor cells overexpressing EGFR and HER3, inducing immunogenic cell death, while JS213 enhances the anti-tumor immune response by blocking the PD-1/PD-L1 inhibitory pathway and selectively activating IL-2 receptors on T cells. The combination is currently undergoing Phase II clinical evaluation for the treatment of advanced malignant solid tumors, including renal cell carcinoma, prostate cancer, urothelial carcinoma, and melanoma.